SCNX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• In connection with our $11 million financing facility with Streeterville that we established in April 2026, we formed a wholly owned subsidiary—SCNX Holdings, LLC (“SCNX Sub”). SCNX Sub exists solely in connection with the financing facility and has no operations. At closing of the financing facilit…

• During the year ended December 31, We previously were known as TRxADE HEALTH, Inc. and operated a web-based market platform focused on enhancing commerce among healthcare participants, a licensed pharmaceutical wholesaler, and a digital telehealth company, through our ownership of Softell Inc. (f/k/…

• Our vision is to be a leader in the industry by developing and commercializing new branded pharmaceutical products for the treatment of CNS and CVS diseases and across other therapeutic areas. Key elements of our strategy to achieve this vision include:

• ● Advance product candidates through clinical studies and toward commercialization. The product candidates in our pipeline are at various stages of clinical development. We intend to move these programs efficiently toward being commercially available to patients, subject to approval by the U.S. Food…

• ● Drive growth and profitability. Using dedicated sales and marketing resources in the U.S., which we are in the process of building, we will seek to begin to generate revenues and then drive the revenue growth of our product candidates approved for marketing by the FDA.

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• After our acquisition of Scienture, we existed as a holding company owning all equity interests of Softell Inc. (f/k/a Trxade Inc.) (“Softell”), Integra Pharma Solutions, LLC d.b.a. Trxade Prime (“IPS”), Bonum Health, LLC, Bonum Health Inc., and Scienture.

• On October 4, 2024, the Company and Softell entered into IPS Assignment Agreement, pursuant to which the Company transferred, and Softell accepted, 100% of the membership interests of IPS. As a result, IPS became a wholly-owned subsidiary of Softell. During the year ended December 31, 2023 and a por…

• On September 20, 2024, the Company fil changed its legal name from “TRxADE HEALTH, Inc.” to “Scienture Holdings, Inc.”

• Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “Bonum Health Hub” was launched in February 2020; however, the Company does not anticipate installations moving forward. On April 30, 2025, the Company completed the sale of Bonum Health, Inc. and Bonum Heal…

• On April 8, 2025, the Company entered into a Membership Interest Purchase Agreement (the “IPS MIPA”) with Tollo Health, LLC (“Tollo”), pursuant to which Tollo agreed to purchase and the Company agreed to sell all of the Company’s membership interests in IPS.

Text added vs the prior filing · source: 10-Q · 2026-08-13

• (c) During the quarter ended June 30, 2026, Dr. Shankar Hariharan, our Executive Chairman and Co-Chief Executive Officer, entered into a “Rule 10b5-1 trading arrangement” (the “Sales Plan”) as that term is defined in Item 408(a) of Regulation S-K. The Sales Plan was adopted on June 3, 2026, and was …

• No other officer or director adopted or terminated (1) a plan, contract, or set of instructions intended to by covered by the 10b5-1 affirmative defense or (2) a written trading arrangement as defined in Item 408(c) of Regulation S-K.

Text removed vs the prior filing · source: 10-Q · 2026-05-15

• (c) During the quarter ended March 31, 2026, no officer or director adopted or terminated (1) a plan, contract, or set of instructions intended to by covered by the 10b5-1 affirmative defense or (2) a written trading arrangement as defined in Item 408(c) of Regulation S-K.